New Products

November 1, 2004



For more information call Debra Phelps at 267-987-3638, or visit the product Web site: http://www.maternityalert.com.

FDA approves two drug combos for treating HIV The Food and Drug Administration has okayed two fixed-dose combination treatments for HIV-1: Epzicom (abacavir/lamivudine) and Truvada (tenofovir disoproxil/emtricitabine). Controlling HIV/AIDS usually requires simultaneous use of three or more drugs from different classes. Combination products bring together different AIDS drugs in a single medication or co-package to simplify patients' treatment regimens. The two drugs are indicated in combination with other antiretroviral drug products from different classes such as non-nucleoside reverse transcriptase inhibitors or protease inhibitors for treating adults with HIV-1 infection.

Truvada (made by Gilead Sciences, Inc.) is a fixed-dose combination of tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg), previously approved individually under the brand names Viread and Emtriva, respectively. Epzicom's approval is based on data showing therapeutic equivalence between the combination product and the individual products. For more information, visit the following Web sites: http://www.fda.gov , http://www.glaxosmithkline.com , and http://www.gilead.com.

For more information, visit the publisher's Web site at http://www.rodalestore.com, then search for the title or author.